NasdaqGM:NTLABiotechs
Why Intellia Therapeutics (NTLA) Is Down 10.6% After Advancing Lonvo-z Toward FDA Review And Commercialization
Intellia Therapeutics recently reported additional positive results from its Phase 3 HAELO trial of gene-editing therapy lonvo-z for hereditary angioedema at the EAACI 2026 Congress in Istanbul, showing strong reductions in attack rates and high proportions of attack- and therapy-free patients.
The company has also begun a rolling biologics license application with the FDA for lonvo-z, signaling that its first potential commercial gene-editing therapy may be moving closer to the market and...